Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

RTI Biologics Gets 510(k) Clearance From FDA For Porcine Dermis Implant

RELATED NEWS
Trade RTIX now with 
3/13/2013 7:51 AM ET

RTI Biologics Inc. (RTIX: Quote), a provider of orthopedic and other biologic implants, said has received 510(k) clearance from the U.S. Food and Drug Administration or FDA for its porcine dermis implant. The implant is planned for use in soft tissue repair procedures such as hernia repair.

Stored hydrated and ready-to-use, the porcine dermis implant consists of non-crosslinked porcine dermis, designed to act as a scaffold that allows for neovascularization and reincorporation with the patient's own tissue.

The implant, would be made available in various shapes and sizes, is sterilized through the Tutoplast Tissue Sterilization Process, a chemical process to sterilize and preserve tissue for implantation. Since the first clinical use in 1971, there has been zero incidence of implant-associated infection from millions of implants sterilized through the process.

The company added that the implants would be processed at RTI's facility in Neunkirchen, Germany for commercial distribution in the U.S. later this year. The facility has been validated for processing and has begun production of the implants.

Click here to receive FREE breaking news email alerts for RTI Biologics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The Reserve Bank of New Zealand on Thursday raised its Official Cash Rate by 25 basis points, to 3.00 percent from 2.75 percent. The decision was in line with expectations, and it marks the second straight month with a rate hike following 24 straight meetings in which the rate was not changed. New Zealand's economic expansion has considerable momentum, with GDP estimated to have grown by 3.5 percent in the year to March. Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter. Stocks moved mostly lower during trading on Wednesday, giving back some ground after trending higher over the past several sessions. Selling pressure was relatively subdued, however, limiting the downside for the markets. The major averages all closed in the red, although the tech-heavy Nasdaq underperformed its counterparts by a wide margin.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.